**Genetic Obesity Syndromes**

**I. Sadaf Farooqi, MD PhD,** University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. isf20@cam.ac.uk

**Updated** **December 12, 2024**

**ABSTRACT**

Genetic factors play a major role in the regulation of body weight and in the susceptibility to obesity in the population. A subset of people with severe obesity carry rare, highly penetrant genetic variants that can result in severe childhood-onset obesity. Current estimates suggest that up to 20% of children with severe obesity may carry pathogenic chromosomal abnormalities or mutations. The diagnosis of a genetic obesity syndrome can provide information that has value for the patient and their family and may help them deal with the social stigma that comes with severe obesity in childhood. In an increasing number of cases, the finding of a genetic cause for a patient’s obesity can inform clinical care and the use of targeted therapies.

**INTRODUCTION**

At a population level, obesity is driven by an increase in the intake of easily available, energy-dense, highly palatable foods and a decrease in physical activity at school/work and in leisure time. However, variation in body mass index (BMI: weight in kg/height in meters squared) within the population is influenced by genetic factors ([1](#_ENREF_1),[2](#_ENREF_2)). Studies in twins and families have shown that food intake, satiety responsiveness (fullness after a fixed meal), basal metabolic rate, the amount of energy utilized during a fixed amount of exercise, and body fat distribution are all heritable traits ([3](#_ENREF_3)).

Genome-wide association studies (GWAS’s) in large population-based cohorts have identified thousands of common variants (minor allele frequency > 5%) that are associated with BMI and/or obesity ([4](#_ENREF_4)). While individually each variant often has a small effect on BMI, cumulatively, the effect of millions of common and rare variants can now be combined to compute a polygenic risk score which can predict the development of severe obesity ([5](#_ENREF_5)). Studies are ongoing to test how such scores might be useful in the clinical setting. Most common obesity associated variants lie in noncoding areas of the genome so identifying the mechanism by which they affect body weight can be challenging. It is interesting to note that most obesity- or BMI-associated variants lie in or near genes which are expressed in the brain and some of these variants have been associated with increased food intake ([4](#_ENREF_4),[6](#_ENREF_6)). In contrast, GWAS associations for body fat distribution/waist-to-hip ratio, mostly seem to be linked to genes expressed in adipose tissue ([7](#_ENREF_7)).

**CLINICAL APPROACH TO DIAGNOSIS OF GENETIC OBESITY SYNDROMES**

Rare (less than 1% minor allele frequency), highly penetrant genetic variants in multiple genes have been associated with severe obesity that often presents in childhood. Whilst these disorders are rare, cumulatively up to 20% of children with severe obesity have chromosomal abnormalities or other penetrant rare variants that drive their obesity ([8](#_ENREF_8)). The assessment of children and adults with severe obesity should be directed at screening for endocrine, neurological, and genetic disorders ([9](#_ENREF_9)). Important information can be obtained from a detailed family history to identify potential consanguineous relationships, the presence of other family members with severe obesity and those who have had bariatric surgery, and the ethnic origin of family members (Figure 1). The clinical history and examination can then guide the appropriate use of diagnostic tests. For the purposes of clinical assessment, it remains useful to categorize the genetic obesity syndromes as those with and without associated developmental delay.



**Figure 1. Diagnosis of genetic obesity syndromes.**

**OBESITY SYNDROMES WITHOUT DEVELOPMENTAL DELAY**

The adipocyte-derived hormone leptin acts mainly to defend against starvation ([10](#_ENREF_10)), with a fall in leptin levels (as seen in weight loss, acute caloric restriction or congenital leptin deficiency) causing an increase in food intake and physiological responses that act to restore energy balance ([11](#_ENREF_11)). In most people, circulating leptin levels correlate closely with fat mass ([12](#_ENREF_12)), although there is considerable variation in leptin levels at any given BMI, which is as yet unexplained. Leptin signals through the long isoform of the leptin receptor, which is widely expressed in the hypothalamus and other brain regions involved in energy homeostasis ([13](#_ENREF_13)). In the arcuate nucleus of the hypothalamus (which has a permeable blood-brain barrier), there are several neuronal populations known to be important in weight regulation expressing the leptin receptor. In the fed state, leptin stimulates the expression of pro-opiomelanocortin (POMC), which is processed to generate the melanocortin peptides that, in turn, activate the melanocortin 4 receptor (MC4R) on second-order neurons in the paraventricular nucleus. Leptin also inhibits adjacent neurons containing Agouti-related protein (AgRP), a MC4R antagonist. The integration of these two actions leads to reduced food intake (Figure 2). In the fasted state and with weight loss, a drop in leptin levels reduces the activation state of POMC neurons and increases AgRP signaling to cause an increase in food intake. These hypothalamic pathways interact with other brain centers to affect not just eating behaviors but also energy expenditure.

Severe obesity can result from mutations that disrupt key components of the leptin-melanocortin pathway (Figure 2). People with these genetic disorders experience an intense drive to eat (hunger), find food to be highly rewarding, and have impaired fullness (satiety) leading to hyperphagia (increased food intake), resulting in excessive weight gain from early childhood.



**Figure 2. Genes involved in the leptin-melanocortin pathway whose disruption causes obesity.**

**Leptin and Leptin Receptor Deficiency**

Congenital leptin (LEP protein; *LEP* gene) and leptin receptor (LEPR protein; *LEPR* gene) deficiency are rare, autosomal recessive disorders associated with severe obesity from a very young age (before 1 year) ([14](#_ENREF_14),[15](#_ENREF_15)). Homozygous frameshift, nonsense, and missense mutations involving *LEP* and *LEPR* have been identified in 1% and 2-3% of patients with severe obesity from consanguineous families, respectively ([16-18](#_ENREF_16)). Leptin receptor mutations have been found in some non-consanguineous families, where both parents were unrelated but carried rare heterozygous variants.

Serum leptin is a useful test in patients with severe early onset obesity as an undetectable serum leptin suggests a diagnosis of congenital leptin deficiency. Very rare mutations that result in a detectable but bio-inactive form of leptin or a form of leptin that antagonizes the leptin receptor, have also been described ([19](#_ENREF_19),[20](#_ENREF_20)). Serum leptin concentrations are appropriate for the degree of obesity in leptin receptor deficiency and as such an elevated serum leptin concentration is not necessarily a predictor of leptin receptor deficiency ([17](#_ENREF_17)). In some patients, particular *LEPR* mutations that result in abnormal cleavage of the extracellular domain of LEPR (which then acts as a leptin binding protein), are associated with markedly elevated leptin levels ([15](#_ENREF_15)).

The clinical phenotypes associated with leptin and leptin receptor deficiencies are similar. Patients are born of normal birth weight, experience intense hyperphagia with food seeking behavior and rapid weight gain in the first few months of life resulting in severe obesity ([16](#_ENREF_16)). While measurable changes in resting metabolic rate or total energy expenditure have not been demonstrated in affected individuals, reduced sympathetic nerve function is associated with impaired fat oxidation and may contribute to obesity ([21](#_ENREF_21)). Children with leptin deficiency have abnormalities of T cell number and function ([16](#_ENREF_16)), consistent with reported high childhood infection rates and childhood mortality from infection, particularly in environments where infectious diseases are prevalent ([21](#_ENREF_21)).

In keeping with severe obesity, patients with leptin and leptin receptor deficiency are hyperinsulinemic and some adults develop type 2 diabetes in the 3rd to 4th decade. Affected individuals can exhibit hypothalamic (secondary) hypothyroidism characterized by low free thyroxine levels and inappropriately normal (or high-normal) levels of serum thyroid stimulating hormone (TSH) ([14](#_ENREF_14),[15](#_ENREF_15)). Typically, adults with leptin or leptin receptor deficiency have biochemical evidence of hypogonadotropic hypogonadism and do not undergo normal pubertal development (see below). However, there are reports of delayed spontaneous onset of menses in some leptin and leptin receptor deficient adults ([17](#_ENREF_17)). Linear growth is appropriate in childhood, but in the absence of a pubertal growth spurt, final height is reduced.

Although leptin deficiency is very rare, it is entirely treatable with daily subcutaneous injections of recombinant human leptin ([16](#_ENREF_16),[22](#_ENREF_22)). The major effect of leptin replacement in these patients is on food intake, with normalization of hyperphagia and enhanced satiety. Leptin administration does not enhance energy expenditure. However, weight loss by caloric restriction is associated with decreased total energy expenditure; the absence of this decrease in patients with congenital leptin deficiency, suggests that leptin does affect energy expenditure ([23](#_ENREF_23)). Leptin replacement permits progression of appropriately-timed pubertal development, along with expression of secondary sexual characteristics ([21](#_ENREF_21)). These reproductive system effects are likely mediated through leptin action on hypothalamic neurons containing kisspeptin, which signals via GPR54 to modify the release of gonadotrophin-releasing hormone ([24](#_ENREF_24)).

Although leptin treatment is not be effective for patients with LEPR deficiency, these patients can now treated with a melanocortin receptor agonist (setmelanotide, Figure 3), which is now licensed in the UK, Europe and USA ([25](#_ENREF_25)).

Leptin treatment is not clinically effective in people with common obesity ([26](#_ENREF_26),[27](#_ENREF_27)), which may be a manifestation of leptin resistance or defects in downstream neuronal pathways. Studies in heterozygous carriers of LEP mutations who have partial leptin deficiency and an increase in fat mass ([28](#_ENREF_28)), suggest that people with relatively low leptin levels may benefit from leptin therapy.

**Pro-opiomelanocortin Deficiency**

Due to impaired production of melanocortin stimulating hormone peptides (a/b MSH) and diminished or absent MC4R signaling (Figure 2), homozygous or compound heterozygous mutations in *POMC* cause hyperphagia and early-onset obesity ([29](#_ENREF_29)). People deficient in POMC also have pale skin and red or light colored hair due to the lack of signaling of pigment-inducing melanocortin 1 receptors in the skin ([29](#_ENREF_29)). In the pituitary gland, POMC is the precursor for adrenocorticotrophin (ACTH). As such, complete POMC deficiency presents in neonatal life with features of ACTH and cortisol deficiency: hypoglycemia and cholestatic jaundice requiring long-term corticosteroid replacement therapy ([30](#_ENREF_30)). Typically, patients with primary or secondary cortisol deficiency present with hypophagia and weight loss, so adrenal insufficiency with hyperphagia in the absence of a structural hypothalamic abnormality should raise suspicion for a POMC defect. POMC deficiency may also impair the timing of puberty, an effect that appears to be mediated by the melanocortin 3 receptor (MC3R) ([31](#_ENREF_31)).

Complete POMC deficiency can be treated with a melanocortin receptor agonist (setmelanotide) ([32](#_ENREF_32)) (Figure 3). Heterozygous missense mutations directly affecting the function of POMC peptides have been described (Figure 2) ([33](#_ENREF_33)). These variants significantly increase obesity risk but are not invariably associated with obesity. The potential efficacy of MC4R agonists in patients with these heterozygous mutations is currently being tested in clinical trials.

****

**Figure 3. Medical treatment of patients with genetic obesity syndromes. POMC: pro-opiomelanocortin. PCSK1: prohormone convertase-1. MC4R: melanocortin 4 receptor. GLP-1: glucagon receptor-1.**

**Prohormone Convertase-1-Deficiency**

Prohormone convertase-1 (PCSK1, also known as PC1/3) is an enzyme that acts upon a range of substrates including proinsulin, proglucagon, and POMC. Compound heterozygous or homozygous mutations in *PCSK1* cause neonatal small bowel enteropathy, glucocorticoid deficiency (secondary to ACTH deficiency), hypogonadotropic hypogonadism, and postprandial hypoglycemia due to impaired processing of proinsulin to insulin, as well as severe, early onset obesity ([34](#_ENREF_34),[35](#_ENREF_35)). Elevated plasma levels of proinsulin and 32/33 split proinsulin in the context of low levels of mature insulin are diagnostic for this disorder. Setmelanotide is now licensed for the treatment of this condition (Figure 3).

**Melanocortin 4 Receptor Deficiency**

Heterozygous melanocortin 4 receptor (MC4R) mutations have been reported in people with obesity from various ethnic groups ([www.mc4r.org.uk](http://www.mc4r.org.uk)) and occur at a frequency of 1 in 300 people in the population ([36](#_ENREF_36)), 1% of adults with a BMI > 30 kg/m2, and 3-5% of children with severe obesity ([37](#_ENREF_37),[38](#_ENREF_38)). *MC4R* mutations are inherited in a co-dominant manner, with variable penetrance and expression; homozygous mutations have also been reported. In several studies, MC4R deficiency is the most common genetic form of obesity ([37-39](#_ENREF_37)).

Given the importance of MC4R for leptin signaling (Figure 2), the clinical features of MC4R deficiency include hyperphagia and rapid weight gain, which often emerges in the first few years of life. Alongside the increase in fat mass, MC4R-deficient subjects also have an increase in lean mass and a marked increase in bone mineral density that exceeds what would be expected for their increased body size and, thus, they often appear “big-boned” ([37](#_ENREF_37)). They exhibit accelerated linear growth in early childhood, which may be a consequence of disproportionate early hyperinsulinemia and effects on pulsatile growth hormone (GH) secretion, which is retained in MC4R-deficient adults in contrast to common forms of obesity ([40](#_ENREF_40)). Despite this early hyperinsulinemia, adult subjects with obesity who are heterozygous for mutations in the MC4R gene have a comparable risk of developing impaired glucose intolerance and type 2 diabetes to controls of similar age and adiposity. Reduced sympathetic nervous system activity in MC4R-deficient patients is likely to explain the lower prevalence of hypertension and lower systolic and diastolic blood pressures compared to control populations ([41](#_ENREF_41)). Thus, central melanocortin signaling appears to play an important role in the regulation of blood pressure and its coupling to changes in weight.

At present, there is no specific therapy for MC4R deficiency, but patients with heterozygous MC4R mutations do respond to Glucagon-like peptide- (GLP-1) receptor agonists ([42](#_ENREF_42)) and to Roux-en-Y-bypass surgery ([43](#_ENREF_43)) (Figure 3), with a variation in weight loss response that is comparable to people with a normal MC4R gene sequence.

**Albright’s Hereditary Osteodystrophy/Pseudohypoparathyroidism**

Albright hereditary osteodystrophy (AHO) is an autosomal dominant disorder due to germline mutations in *GNAS*, an imprinted gene that encodes the G alpha s (Gs) protein, which mediates signaling by multiple G-protein coupled receptors (GPCRs). Classically, heterozygous loss-of-function mutations in GNAS affecting the maternal allele lead to short stature, obesity, skeletal defects, and resistance to several hormones that activate Gs in their target tissues (pseudohypoparathyroidism type IA), while paternal transmission leads only to the AHO phenotype (pseudopseudohypoparathyroidism) ([44](#_ENREF_44)). GNAS mutations affect coupling to, or signaling by, MC4R, which explains hyperphagia and obesity in affected patients ([45](#_ENREF_45)). Some patients will carry mutations that affect signaling by other GPCRs including the beta-2 and beta-3 adrenoreceptors which contribute to low basal metabolic rate and other clinical phenotypes ([45](#_ENREF_45)). These patients may not have classical features such as short stature. As such, this diagnosis should be considered in all patients with severe early-onset obesity ([45](#_ENREF_45)).

**SRC Homology 2B (SH2B1) 1 Deficiency**

Deletion of a 220-kb segment of chromosome 16p11.2 is associated with highly penetrant, severe, early-onset obesity and insulin resistance ([46](#_ENREF_46)). This deletion includes a small number of genes, one of which is *SH2B1* (Src homology 2B1) known to be involved in leptin, insulin, and Brain-Derived Neurotrophic Factor (BDNF) signaling. These patients gain weight in the first years of life, with hyperphagia and fasting plasma insulin levels that are disproportionately elevated, with increased risk for type 2 diabetes in early adulthood ([47](#_ENREF_47)). In some patients loss of function mutations in the SH2B1 gene have also been reported in association with early-onset obesity, severe insulin resistance, and behavioral abnormalities ([48](#_ENREF_48)).

**OBESITY SYNDROMES WITH DEVELOPMENTAL DELAY**

**Prader-Willi Syndrome**

Prader-Willi syndrome is an autosomal dominant disorder caused by deletion or disruption of a paternally imprinted region on chromosome 15q11.2-q12 ([49](#_ENREF_49)). The clinical features of Prader-Willi syndrome (PWS) include diminished fetal activity, hypotonia, and feeding difficulties in infancy followed by hyperphagia, obesity, developmental delay, short stature, hypogonadotropic hypogonadism, and small hands and feet (Figure 4). Children with PWS display diminished growth, reduced lean body mass and increased fat mass. These body composition abnormalities can be explained, in part, by growth hormone (GH) deficiency and improved with growth hormone treatment, which should be started in early childhood.



**Figure 4.** **Infancy and childhood clinical features of Prader-Willi Syndrome (PWS).**

Contained within the 4.5Mb PWS region in 15q11-q13 are silenced paternally imprinted genes and a family of small nucleolar RNAs (snoRNAs) known as the HBII-85 snoRNAs. Small deletions exclusively encompassing these snoRNAs result in the key features of PWS including obesity (Figure 4) ([50](#_ENREF_50),[51](#_ENREF_51)), suggesting that these snoRNAs play a critical role in the development of this syndrome. Histopathological studies on post-mortem brain samples from PWS patients have demonstrated reduced levels of oxytocin expression in the hypothalamus ([52](#_ENREF_52)) and trials of intranasal administration in PWS are ongoing ([53](#_ENREF_53)). Brain-derived neurotrophic factor (BDNF) expression is also reduced in PWS, potentially contributing to both the obesity and neurobehavioral features including stereotyped behaviors ([54](#_ENREF_54)).

**Bardet Biedl Syndrome**

Bardet-Biedl syndrome (BBS) is a rare, autosomal recessive disease caused by mutations in over 25 genes and characterized by obesity, developmental delay, syndactyly, brachydactyly or polydactyly, retinal dystrophy or pigmentary retinopathy, hypogonadism, and structural abnormalities of the kidney or renal impairment ([55](#_ENREF_55)). The differential diagnosis includes Biemond syndrome II (iris coloboma, hypogenitalism, obesity, polydactyly) and Alstrom syndrome (retinitis pigmentosa, obesity, diabetes mellitus, and deafness). To date, BBS proteins are all involved in basal body and centrosomal function and impact on ciliary development and transport ([56](#_ENREF_56)). There is some evidence that BBS genes affect leptin signaling and trafficking of MC4Rs in cilia. Clinical trials of setmelanotide have shown some benefit in treating hyperphagia in these patients ([57](#_ENREF_57)) and this drug is licensed for BBS in some countries (Figure 3).

**Brain-Derived Neurotrophic Factor and Tropomycin-Related Kinase B**

Brain-Derived neurotrophic factor (BDNF) activates signaling by the tropomycin-related kinase B (TrkB) to play a key role in the development and maintenance of neurons. Rare chromosomal rearrangements and heterozygous point mutations in BDNF and TrkB are associated with speech and language delay, hyperphagia, and impaired pain sensation ([58-60](#_ENREF_58)). Disordered behaviors including hyperactivity, fearlessness, anxiety, and aggression are also features of these conditions, which can often present as de-novo genetic abnormalities ([61](#_ENREF_61)).

**Single Minded 1 Deficiency**

Single minded 1 (SIM1) is a transcription factor involved in the development of the paraventricular and supraoptic nuclei of the hypothalamus. Chromosomal rearrangements and heterozygous missense mutations in SIM1 and in a closely related transcription factor OTP (Orthopedia) cause severe obesity ([62-64](#_ENREF_62)). Clinical features of these patients resemble those seen in MC4R deficiency with, in addition, a variable phenotype of developmental delay with autistic like features noted in some, but not all, patients ([63](#_ENREF_63)).

**Other Rare Genetic Mutations**

Rare penetrant variants in multiple genes can be associated with, but do not invariably cause, obesity that is inherited in a classical Mendelian manner (Figure 2). Examples include heterozygous loss of function variants affecting the Semaphorin 3 ligands, receptors and co-receptors that direct the development of POMC projections ([65](#_ENREF_65)); mutations in Steroid receptor coactivator-1 (*SRC-1*) ([66](#_ENREF_66))andPleckstrin-homology-domain interacting protein, *PHIP*, which modulate POMC transcription ([67](#_ENREF_67)); disruption of Serotonin 2c receptor, *HTR2C* which regulates the electrical activity of POMC neurons causing obesity, social anxiety and impaired memory ([68](#_ENREF_68),[69](#_ENREF_69)) and deletions affecting TRPC5 on the X chromosome, which cause obesity, anxiety, autism (in males), and postnatal depression (in females) ([70](#_ENREF_70)). Variants in genes that regulate MC4R trafficking *(MRAP2*) ([71](#_ENREF_71)) and genes whose precise function in the hypothalamus is not as yet clear, such as Kinase Suppressor of Ras-2 (*KSR2*) ([72](#_ENREF_72)) have also been associated with obesity.

**FUTURE PERSPECTIVES**

The diagnosis of a genetic obesity syndrome can provide information that has diagnostic value for the family to whom genetic counselling can be provided. A genetic diagnosis can help children and their families deal with the social stigma that comes with severe obesity and, in some instances, has prevented children from being taken into care by social services when obesity is blamed on parental neglect. A genetic diagnosis can inform management (many such patients are relatively refractory to weight loss through changes in diet and exercise) and can inform clinical decision-making. For example, bariatric surgery (particularly Roux-en-Y bypass surgery) is contraindicated in many genetic obesity syndromes as it does not reverse the strong hypothalamic drive to eat and continued overeating can be harmful. Importantly, an increasing number of genetic obesity syndromes are now treatable with mechanism-based pharmacologic therapies.

**REFERENCES**

1. Maes HH, Neale MC, Eaves LJ. Genetic and environmental factors in relative body weight and human adiposity. *Behav Genet*.1997;27(4):325-351.

2. Stunkard AJ HJ, Pedersen NL, McClearn GE. The body-mass index of twins who have been reared apart. *N Engl J Med*.1990;322:1483-1487.

3. Bouchard C. Genetics of Obesity: What We Have Learned Over Decades of Research. *Obesity (Silver Spring)*.2021;29(5):802-820.

4. Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. *Nature reviews Genetics*.2022;23(2):120-133.

5. Khera AV, Chaffin M, Wade KH, Zahid S, Brancale J, Xia R, Distefano M, Senol-Cosar O, Haas ME, Bick A, Aragam KG, Lander ES, Smith GD, Mason-Suares H, Fornage M, Lebo M, Timpson NJ, Kaplan LM, Kathiresan S. Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood. *Cell*.2019;177(3):587-596 e589.

6. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, Yang J, Croteau-Chonka DC, Esko T, Fall T, Ferreira T, Gustafsson S, Kutalik Z, Luan J, Magi R, Randall JC, Winkler TW, Wood AR, Workalemahu T, Faul JD, Smith JA, Zhao JH, Zhao W, Chen J, Fehrmann R, Hedman AK, Karjalainen J, Schmidt EM, Absher D, Amin N, Anderson D, Beekman M, Bolton JL, Bragg-Gresham JL, Buyske S, Demirkan A, Deng G, Ehret GB, Feenstra B, Feitosa MF, Fischer K, Goel A, Gong J, Jackson AU, Kanoni S, Kleber ME, Kristiansson K, Lim U, Lotay V, Mangino M, Leach IM, Medina-Gomez C, Medland SE, Nalls MA, Palmer CD, Pasko D, Pechlivanis S, Peters MJ, Prokopenko I, Shungin D, Stancakova A, Strawbridge RJ, Sung YJ, Tanaka T, Teumer A, Trompet S, van der Laan SW, van Setten J, Van Vliet-Ostaptchouk JV, Wang Z, Yengo L, Zhang W, Isaacs A, Albrecht E, Arnlov J, Arscott GM, Attwood AP, Bandinelli S, Barrett A, Bas IN, Bellis C, Bennett AJ, Berne C, Blagieva R, Bluher M, Bohringer S, Bonnycastle LL, Bottcher Y, Boyd HA, Bruinenberg M, Caspersen IH, Chen YI, Clarke R, Daw EW, de Craen AJM, Delgado G, Dimitriou M, Doney ASF, Eklund N, Estrada K, Eury E, Folkersen L, Fraser RM, Garcia ME, Geller F, Giedraitis V, Gigante B, Go AS, Golay A, Goodall AH, Gordon SD, Gorski M, Grabe HJ, Grallert H, Grammer TB, Grassler J, Gronberg H, Groves CJ, Gusto G, Haessler J, Hall P, Haller T, Hallmans G, Hartman CA, Hassinen M, Hayward C, Heard-Costa NL, Helmer Q, Hengstenberg C, Holmen O, Hottenga JJ, James AL, Jeff JM, Johansson A, Jolley J, Juliusdottir T, Kinnunen L, Koenig W, Koskenvuo M, Kratzer W, Laitinen J, Lamina C, Leander K, Lee NR, Lichtner P, Lind L, Lindstrom J, Lo KS, Lobbens S, Lorbeer R, Lu Y, Mach F, Magnusson PKE, Mahajan A, McArdle WL, McLachlan S, Menni C, Merger S, Mihailov E, Milani L, Moayyeri A, Monda KL, Morken MA, Mulas A, Muller G, Muller-Nurasyid M, Musk AW, Nagaraja R, Nothen MM, Nolte IM, Pilz S, Rayner NW, Renstrom F, Rettig R, Ried JS, Ripke S, Robertson NR, Rose LM, Sanna S, Scharnagl H, Scholtens S, Schumacher FR, Scott WR, Seufferlein T, Shi J, Smith AV, Smolonska J, Stanton AV, Steinthorsdottir V, Stirrups K, Stringham HM, Sundstrom J, Swertz MA, Swift AJ, Syvanen AC, Tan ST, Tayo BO, Thorand B, Thorleifsson G, Tyrer JP, Uh HW, Vandenput L, Verhulst FC, Vermeulen SH, Verweij N, Vonk JM, Waite LL, Warren HR, Waterworth D, Weedon MN, Wilkens LR, Willenborg C, Wilsgaard T, Wojczynski MK, Wong A, Wright AF, Zhang Q, LifeLines Cohort S, Brennan EP, Choi M, Dastani Z, Drong AW, Eriksson P, Franco-Cereceda A, Gadin JR, Gharavi AG, Goddard ME, Handsaker RE, Huang J, Karpe F, Kathiresan S, Keildson S, Kiryluk K, Kubo M, Lee JY, Liang L, Lifton RP, Ma B, McCarroll SA, McKnight AJ, Min JL, Moffatt MF, Montgomery GW, Murabito JM, Nicholson G, Nyholt DR, Okada Y, Perry JRB, Dorajoo R, Reinmaa E, Salem RM, Sandholm N, Scott RA, Stolk L, Takahashi A, Tanaka T, van 't Hooft FM, Vinkhuyzen AAE, Westra HJ, Zheng W, Zondervan KT, Consortium AD, Group A-BW, Consortium CAD, Consortium CK, Glgc, Icbp, Investigators M, Mu TC, Consortium MI, Consortium P, ReproGen C, Consortium G, International Endogene C, Heath AC, Arveiler D, Bakker SJL, Beilby J, Bergman RN, Blangero J, Bovet P, Campbell H, Caulfield MJ, Cesana G, Chakravarti A, Chasman DI, Chines PS, Collins FS, Crawford DC, Cupples LA, Cusi D, Danesh J, de Faire U, den Ruijter HM, Dominiczak AF, Erbel R, Erdmann J, Eriksson JG, Farrall M, Felix SB, Ferrannini E, Ferrieres J, Ford I, Forouhi NG, Forrester T, Franco OH, Gansevoort RT, Gejman PV, Gieger C, Gottesman O, Gudnason V, Gyllensten U, Hall AS, Harris TB, Hattersley AT, Hicks AA, Hindorff LA, Hingorani AD, Hofman A, Homuth G, Hovingh GK, Humphries SE, Hunt SC, Hypponen E, Illig T, Jacobs KB, Jarvelin MR, Jockel KH, Johansen B, Jousilahti P, Jukema JW, Jula AM, Kaprio J, Kastelein JJP, Keinanen-Kiukaanniemi SM, Kiemeney LA, Knekt P, Kooner JS, Kooperberg C, Kovacs P, Kraja AT, Kumari M, Kuusisto J, Lakka TA, Langenberg C, Marchand LL, Lehtimaki T, Lyssenko V, Mannisto S, Marette A, Matise TC, McKenzie CA, McKnight B, Moll FL, Morris AD, Morris AP, Murray JC, Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Madden PAF, Pasterkamp G, Peden JF, Peters A, Postma DS, Pramstaller PP, Price JF, Qi L, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ridker PM, Rioux JD, Ritchie MD, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schunkert H, Schwarz PEH, Sever P, Shuldiner AR, Sinisalo J, Stolk RP, Strauch K, Tonjes A, Tregouet DA, Tremblay A, Tremoli E, Virtamo J, Vohl MC, Volker U, Waeber G, Willemsen G, Witteman JC, Zillikens MC, Adair LS, Amouyel P, Asselbergs FW, Assimes TL, Bochud M, Boehm BO, Boerwinkle E, Bornstein SR, Bottinger EP, Bouchard C, Cauchi S, Chambers JC, Chanock SJ, Cooper RS, de Bakker PIW, Dedoussis G, Ferrucci L, Franks PW, Froguel P, Groop LC, Haiman CA, Hamsten A, Hui J, Hunter DJ, Hveem K, Kaplan RC, Kivimaki M, Kuh D, Laakso M, Liu Y, Martin NG, Marz W, Melbye M, Metspalu A, Moebus S, Munroe PB, Njolstad I, Oostra BA, Palmer CNA, Pedersen NL, Perola M, Perusse L, Peters U, Power C, Quertermous T, Rauramaa R, Rivadeneira F, Saaristo TE, Saleheen D, Sattar N, Schadt EE, Schlessinger D, Slagboom PE, Snieder H, Spector TD, Thorsteinsdottir U, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Walker M, Wallaschofski H, Wareham NJ, Watkins H, Weir DR, Wichmann HE, Wilson JF, Zanen P, Borecki IB, Deloukas P, Fox CS, Heid IM, O'Connell JR, Strachan DP, Stefansson K, van Duijn CM, Abecasis GR, Franke L, Frayling TM, McCarthy MI, Visscher PM, Scherag A, Willer CJ, Boehnke M, Mohlke KL, Lindgren CM, Beckmann JS, Barroso I, North KE, Ingelsson E, Hirschhorn JN, Loos RJF, Speliotes EK. Genetic studies of body mass index yield new insights for obesity biology. *Nature*.2015;518(7538):197-206.

7. Rask-Andersen M, Karlsson T, Ek WE, Johansson A. Genome-wide association study of body fat distribution identifies adiposity loci and sex-specific genetic effects. *Nat Commun*.2019;10(1):339.

8. Hendricks AE, Bochukova EG, Marenne G, Keogh JM, Atanassova N, Bounds R, Wheeler E, Mistry V, Henning E, Korner A, Muddyman D, McCarthy S, Hinney A, Hebebrand J, Scott RA, Langenberg C, Wareham NJ, Surendran P, Howson JM, Butterworth AS, Danesh J, Nordestgaard BG, Nielsen SF, Afzal S, Papadia S, Ashford S, Garg S, Millhauser GL, Palomino RI, Kwasniewska A, Tachmazidou I, O'Rahilly S, Zeggini E, Barroso I, Farooqi IS, Understanding Society Scientific G, Consortium E-C, Consortium UK. Rare Variant Analysis of Human and Rodent Obesity Genes in Individuals with Severe Childhood Obesity. *Sci Rep*.2017;7(1):4394.

9. Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, Yanovski JA. Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*.2017;102(3):709-757.

10. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier JS. Role of leptin in the neuroendocrine response to fasting. *Nature*.1996;382(6588):250-252.

11. Flier JS, Maratos-Flier E. Leptin's Physiologic Role: Does the Emperor of Energy Balance Have No Clothes? *Cell metabolism*.2017;26(1):24-26.

12. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. *N Engl J Med*.1996;334(5):292-295.

13. Gautron L, Elmquist JK, Williams KW. Neural control of energy balance: translating circuits to therapies. *Cell*.2015;161(1):133-145.

14. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA, Cheetham CH, Earley AR, Barnett AH, Prins JB, O'Rahilly S. Congenital leptin deficiency is associated with severe early-onset obesity in humans. *Nature*.1997;387(6636):903-908.

15. Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, Gourmelen M, Dina C, Chambaz J, Lacorte JM, Basdevant A, Bougneres P, Lebouc Y, Froguel P, Guy-Grand B. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. *Nature*.1998;392(6674):398-401.

16. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, Sanna V, Jebb SA, Perna F, Fontana S, Lechler RI, DePaoli AM, O'Rahilly S. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. *J Clin Invest*.2002;110(8):1093-1103.

17. Farooqi IS, Wangensteen T, Collins S, Kimber W, Matarese G, Keogh JM, Lank E, Bottomley B, Lopez-Fernandez J, Ferraz-Amaro I, Dattani MT, Ercan O, Myhre AG, Retterstol L, Stanhope R, Edge JA, McKenzie S, Lessan N, Ghodsi M, De Rosa V, Perna F, Fontana S, Barroso I, Undlien DE, O'Rahilly S. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. *N Engl J Med*.2007;356(3):237-247.

18. Saeed S, Bonnefond A, Manzoor J, Shabbir F, Ayesha H, Philippe J, Durand E, Crouch H, Sand O, Ali M, Butt T, Rathore AW, Falchi M, Arslan M, Froguel P. Genetic variants in LEP, LEPR, and MC4R explain 30% of severe obesity in children from a consanguineous population. *Obesity (Silver Spring)*.2015;23(8):1687-1695.

19. Wabitsch M, Funcke JB, Lennerz B, Kuhnle-Krahl U, Lahr G, Debatin KM, Vatter P, Gierschik P, Moepps B, Fischer-Posovszky P. Biologically inactive leptin and early-onset extreme obesity. *N Engl J Med*.2015;372(1):48-54.

20. Funcke JB, Moepps B, Roos J, von Schnurbein J, Verstraete K, Frohlich-Reiterer E, Kohlsdorf K, Nunziata A, Brandt S, Tsirigotaki A, Dansercoer A, Suppan E, Haris B, Debatin KM, Savvides SN, Farooqi IS, Hussain K, Gierschik P, Fischer-Posovszky P, Wabitsch M. Rare Antagonistic Leptin Variants and Severe, Early-Onset Obesity. *N Engl J Med*.2023;388(24):2253-2261.

21. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. *J Clin Endocrinol Metab*.1999;84(10):3686-3695.

22. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. *N Engl J Med*.1999;341(12):879-884.

23. Galgani JE, Greenway FL, Caglayan S, Wong ML, Licinio J, Ravussin E. Leptin replacement prevents weight loss-induced metabolic adaptation in congenital leptin-deficient patients. *J Clin Endocrinol Metab*.2010;95(2):851-855.

24. Navarro VM. Metabolic regulation of kisspeptin — the link between energy balance and reproduction. *Nature Reviews Endocrinology*.2020;16(8):407-420.

25. Clement K, Biebermann H, Farooqi IS, Van der Ploeg L, Wolters B, Poitou C, Puder L, Fiedorek F, Gottesdiener K, Kleinau G, Heyder N, Scheerer P, Blume-Peytavi U, Jahnke I, Sharma S, Mokrosinski J, Wiegand S, Muller A, Weiss K, Mai K, Spranger J, Gruters A, Blankenstein O, Krude H, Kuhnen P. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. *Nat Med*.2018;24(5):551-555.

26. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCamish M. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. *JAMA*.1999;282(16):1568-1575.

27. Zelissen PM, Stenlof K, Lean ME, Fogteloo J, Keulen ET, Wilding J, Finer N, Rössner S, Lawrence E, Fletcher C, McCamish M. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. *Diabetes, obesity & metabolism*.2005;7(6):755-761.

28. Farooqi IS, Keogh JM, Kamath S, Jones S, Gibson WT, Trussell R, Jebb SA, Lip GY, O'Rahilly S. Partial leptin deficiency and human adiposity. *Nature*.2001;414(6859):34-35.

29. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. *Nat Genet*.1998;19(2):155-157.

30. Krude H, Biebermann H, Schnabel D, Tansek MZ, Theunissen P, Mullis PE, Gruters A. Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10. *J Clin Endocrinol Metab*.2003;88(10):4633-4640.

31. Lam BYH, Williamson A, Finer S, Day FR, Tadross JA, Gonçalves Soares A, Wade K, Sweeney P, Bedenbaugh MN, Porter DT, Melvin A, Ellacott KLJ, Lippert RN, Buller S, Rosmaninho-Salgado J, Dowsett GKC, Ridley KE, Xu Z, Cimino I, Rimmington D, Rainbow K, Duckett K, Holmqvist S, Khan A, Dai X, Bochukova EG, Trembath RC, Martin HC, Coll AP, Rowitch DH, Wareham NJ, van Heel DA, Timpson N, Simerly RB, Ong KK, Cone RD, Langenberg C, Perry JRB, Yeo GS, O'Rahilly S. MC3R links nutritional state to childhood growth and the timing of puberty. *Nature*.2021;599(7885):436-441.

32. Kuhnen P, Clement K, Wiegand S, Blankenstein O, Gottesdiener K, Martini LL, Mai K, Blume-Peytavi U, Gruters A, Krude H. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist. *N Engl J Med*.2016;375(3):240-246.

33. Lee YS, Challis BG, Thompson DA, Yeo GS, Keogh JM, Madonna ME, Wraight V, Sims M, Vatin V, Meyre D, Shield J, Burren C, Ibrahim Z, Cheetham T, Swift P, Blackwood A, Hung CC, Wareham NJ, Froguel P, Millhauser GL, O'Rahilly S, Farooqi IS. A POMC variant implicates beta-melanocyte-stimulating hormone in the control of human energy balance. *Cell metabolism*.2006;3(2):135-140.

34. Jackson RS, Creemers JW, Ohagi S, Raffin-Sanson ML, Sanders L, Montague CT, Hutton JC, O'Rahilly S. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. *Nat Genet*.1997;16(3):303-306.

35. Jackson RS, Creemers JW, Farooqi IS, Raffin-Sanson ML, Varro A, Dockray GJ, Holst JJ, Brubaker PL, Corvol P, Polonsky KS, Ostrega D, Becker KL, Bertagna X, Hutton JC, White A, Dattani MT, Hussain K, Middleton SJ, Nicole TM, Milla PJ, Lindley KJ, O'Rahilly S. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. *J Clin Invest*.2003;112(10):1550-1560.

36. Wade KH, Lam BYH, Melvin A, Pan W, Corbin LJ, Hughes DA, Rainbow K, Chen JH, Duckett K, Liu X, Mokrosinski J, Morseburg A, Neaves S, Williamson A, Zhang C, Farooqi IS, Yeo GSH, Timpson NJ, O'Rahilly S. Loss-of-function mutations in the melanocortin 4 receptor in a UK birth cohort. *Nat Med*.2021;27(6):1088-1096.

37. Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. *N Engl J Med*.2003;348(12):1085-1095.

38. Stutzmann F, Tan K, Vatin V, Dina C, Jouret B, Tichet J, Balkau B, Potoczna N, Horber F, O'Rahilly S, Farooqi IS, Froguel P, Meyre D. Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees. *Diabetes*.2008;57(9):2511-2518.

39. Collet TH, Dubern B, Mokrosinski J, Connors H, Keogh JM, Mendes de Oliveira E, Henning E, Poitou-Bernert C, Oppert JM, Tounian P, Marchelli F, Alili R, Le Beyec J, Pepin D, Lacorte JM, Gottesdiener A, Bounds R, Sharma S, Folster C, Henderson B, O'Rahilly S, Stoner E, Gottesdiener K, Panaro BL, Cone RD, Clement K, Farooqi IS, Van der Ploeg LHT. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. *Mol Metab*.2017;6(10):1321-1329.

40. Martinelli CE, Keogh JM, Greenfield JR, Henning E, van der Klaauw AA, Blackwood A, O'Rahilly S, Roelfsema F, Camacho-Hubner C, Pijl H, Farooqi IS. Obesity due to melanocortin 4 receptor (MC4R) deficiency is associated with increased linear growth and final height, fasting hyperinsulinemia, and incompletely suppressed growth hormone secretion. *J Clin Endocrinol Metab*.2011;96(1):E181-188.

41. Greenfield JR, Miller JW, Keogh JM, Henning E, Satterwhite JH, Cameron GS, Astruc B, Mayer JP, Brage S, See TC, Lomas DJ, O'Rahilly S, Farooqi IS. Modulation of blood pressure by central melanocortinergic pathways. *N Engl J Med*.2009;360(1):44-52.

42. Iepsen EW, Zhang J, Thomsen HS, Hansen EL, Hollensted M, Madsbad S, Hansen T, Holst JJ, Holm JC, Torekov SS. Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. *Cell metabolism*.2018;28(1):23-32.e23.

43. Hatoum IJ, Stylopoulos N, Vanhoose AM, Boyd KL, Yin DP, Ellacott KL, Ma LL, Blaszczyk K, Keogh JM, Cone RD, Farooqi IS, Kaplan LM. Melanocortin-4 receptor signaling is required for weight loss after gastric bypass surgery. *J Clin Endocrinol Metab*.2012;97(6):E1023-1031.

44. Weinstein LS, Chen M, Liu J. Gs(alpha) mutations and imprinting defects in human disease. *Ann N Y Acad Sci*.2002;968:173-197.

45. Mendes de Oliveira E, Keogh JM, Talbot F, Henning E, Ahmed R, Perdikari A, Bounds R, Wasiluk N, Ayinampudi V, Barroso I, Mokrosinski J, Jyothish D, Lim S, Gupta S, Kershaw M, Matei C, Partha P, Randell T, McAulay A, Wilson LC, Cheetham T, Crowne EC, Clayton P, Farooqi IS. Obesity-Associated GNAS Mutations and the Melanocortin Pathway. *N Engl J Med*.2021;385(17):1581-1592.

46. Bochukova EG, Huang N, Keogh J, Henning E, Purmann C, Blaszczyk K, Saeed S, Hamilton-Shield J, Clayton-Smith J, O'Rahilly S, Hurles ME, Farooqi IS. Large, rare chromosomal deletions associated with severe early-onset obesity. *Nature*.2010;463(7281):666-670.

47. Hanssen R, Auwerx C, Joeloo M, Sadler MC, Estonian Biobank Research T, Henning E, Keogh J, Bounds R, Smith M, Firth HV, Kutalik Z, Farooqi IS, Reymond A, Lawler K. Chromosomal deletions on 16p11.2 encompassing SH2B1 are associated with accelerated metabolic disease. *Cell Rep Med*.2023;4(8):101155.

48. Doche ME, Bochukova EG, Su HW, Pearce LR, Keogh JM, Henning E, Cline JM, Saeed S, Dale A, Cheetham T, Barroso I, Argetsinger LS, O'Rahilly S, Rui L, Carter-Su C, Farooqi IS. Human SH2B1 mutations are associated with maladaptive behaviors and obesity. *J Clin Invest*.2012;122(12):4732-4736.

49. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. *Genet Med*.2012;14(1):10-26.

50. Sahoo T, del Gaudio D, German JR, Shinawi M, Peters SU, Person RE, Garnica A, Cheung SW, Beaudet AL. Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster. *Nat Genet*.2008;40(6):719-721.

51. de Smith AJ, Purmann C, Walters RG, Ellis RJ, Holder SE, Van Haelst MM, Brady AF, Fairbrother UL, Dattani M, Keogh JM, Henning E, Yeo GS, O'Rahilly S, Froguel P, Farooqi IS, Blakemore AI. A deletion of the HBII-85 class of small nucleolar RNAs (snoRNAs) is associated with hyperphagia, obesity and hypogonadism. *Hum Mol Genet*.2009;18(17):3257-3265.

52. Swaab DF, Purba JS, Hofman MA. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. *J Clin Endocrinol Metab*.1995;80(2):573-579.

53. Tauber M, Boulanouar K, Diene G, Cabal-Berthoumieu S, Ehlinger V, Fichaux-Bourin P, Molinas C, Faye S, Valette M, Pourrinet J, Cessans C, Viaux-Sauvelon S, Bascoul C, Guedeney A, Delhanty P, Geenen V, Martens H, Muscatelli F, Cohen D, Consoli A, Payoux P, Arnaud C, Salles JP. The Use of Oxytocin to Improve Feeding and Social Skills in Infants With Prader-Willi Syndrome. *Pediatrics*.2017;139(2).

54. Bochukova EG, Lawler K, Croizier S, Keogh JM, Patel N, Strohbehn G, Lo KK, Humphrey J, Hokken-Koelega A, Damen L, Donze S, Bouret SG, Plagnol V, Farooqi IS. A Transcriptomic Signature of the Hypothalamic Response to Fasting and BDNF Deficiency in Prader-Willi Syndrome. *Cell Rep*.2018;22(13):3401-3408.

55. Forsythe E, Beales PL. Bardet-Biedl syndrome. *Eur J Hum Genet*.2013;21(1):8-13.

56. Forsythe E, Sparks K, Best S, Borrows S, Hoskins B, Sabir A, Barrett T, Williams D, Mohammed S, Goldsmith D, Milford DV, Bockenhauer D, Foggensteiner L, Beales PL. Risk Factors for Severe Renal Disease in Bardet-Biedl Syndrome. *J Am Soc Nephrol*.2017;28(3):963-970.

57. Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GA, Poitou C, Yanovski JA, Mittleman RS, Yuan G, Forsythe E, Clement K, Argente J. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstrom syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. *The lancet Diabetes & endocrinology*.2022;10(12):859-868.

58. Gray J, Yeo GS, Cox JJ, Morton J, Adlam AL, Keogh JM, Yanovski JA, El Gharbawy A, Han JC, Tung YC, Hodges JR, Raymond FL, O'Rahilly S, Farooqi IS. Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. *Diabetes*.2006;55(12):3366-3371.

59. Han JC, Liu QR, Jones M, Levinn RL, Menzie CM, Jefferson-George KS, Adler-Wailes DC, Sanford EL, Lacbawan FL, Uhl GR, Rennert OM, Yanovski JA. Brain-derived neurotrophic factor and obesity in the WAGR syndrome. *N Engl J Med*.2008;359(9):918-927.

60. Yeo GS, Connie Hung CC, Rochford J, Keogh J, Gray J, Sivaramakrishnan S, O'Rahilly S, Farooqi IS. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. *Nat Neurosci*.2004;7(11):1187-1189.

61. Sonoyama T, Stadler LKJ, Zhu M, Keogh JM, Henning E, Hisama F, Kirwan P, Jura M, Blaszczyk BK, DeWitt DC, Brouwers B, Hyvonen M, Barroso I, Merkle FT, Appleyard SM, Wayman GA, Farooqi IS. Human BDNF/TrkB variants impair hippocampal synaptogenesis and associate with neurobehavioural abnormalities. *Sci Rep*.2020;10(1):9028.

62. Holder LJ, Nancy F. Butte & Andrew R. Zinn. Profound obesity associated with a balanced translocatioin that disrupts the *SIM1* gene. *Hum Mol Genet*.2000;9(1):101-108.

63. Ramachandrappa S, Raimondo A, Cali AM, Keogh JM, Henning E, Saeed S, Thompson A, Garg S, Bochukova EG, Brage S, Trowse V, Wheeler E, Sullivan AE, Dattani M, Clayton PE, Datta V, Bruning JB, Wareham NJ, O'Rahilly S, Peet DJ, Barroso I, Whitelaw ML, Farooqi IS. Rare variants in single-minded 1 (SIM1) are associated with severe obesity. *J Clin Invest*.2013;123(7):3042-3050.

64. Moir L, Bochukova EG, Dumbell R, Banks G, Bains RS, Nolan PM, Scudamore C, Simon M, Watson KA, Keogh J, Henning E, Hendricks A, O'Rahilly S, Barroso I, Sullivan AE, Bersten DC, Whitelaw ML, Kirsch S, Bentley E, Farooqi IS, Cox RD. Disruption of the homeodomain transcription factor orthopedia homeobox (Otp) is associated with obesity and anxiety. *Mol Metab*.2017;6(11):1419-1428.

65. van der Klaauw AA, Croizier S, Mendes de Oliveira E, Stadler LKJ, Park S, Kong Y, Banton MC, Tandon P, Hendricks AE, Keogh JM, Riley SE, Papadia S, Henning E, Bounds R, Bochukova EG, Mistry V, O'Rahilly S, Simerly RB, Interval, Consortium UK, Minchin JEN, Barroso I, Jones EY, Bouret SG, Farooqi IS. Human Semaphorin 3 Variants Link Melanocortin Circuit Development and Energy Balance. *Cell*.2019;176(4):729-742 e718.

66. Cacciottolo TM, Henning E, Keogh JM, Bel Lassen P, Lawler K, Bounds R, Ahmed R, Perdikari A, Mendes de Oliveira E, Smith M, Godfrey EM, Johnson E, Hodson L, Clement K, van der Klaauw AA, Farooqi IS. Obesity Due to Steroid Receptor Coactivator-1 Deficiency Is Associated With Endocrine and Metabolic Abnormalities. *J Clin Endocrinol Metab*.2022;107(6):e2532-e2544.

67. Marenne G, Hendricks AE, Perdikari A, Bounds R, Payne F, Keogh JM, Lelliott CJ, Henning E, Pathan S, Ashford S, Bochukova EG, Mistry V, Daly A, Hayward C, Interval UKKC, Wareham NJ, O'Rahilly S, Langenberg C, Wheeler E, Zeggini E, Farooqi IS, Barroso I. Exome Sequencing Identifies Genes and Gene Sets Contributing to Severe Childhood Obesity, Linking PHIP Variants to Repressed POMC Transcription. *Cell metabolism*.2020;31(6):1107-1119 e1112.

68. He Y, Brouwers B, Liu H, Liu H, Lawler K, Mendes de Oliveira E, Lee DK, Yang Y, Cox AR, Keogh JM, Henning E, Bounds R, Perdikari A, Ayinampudi V, Wang C, Yu M, Tu L, Zhang N, Yin N, Han J, Scarcelli NA, Yan Z, Conde KM, Potts C, Bean JC, Wang M, Hartig SM, Liao L, Xu J, Barroso I, Mokrosinski J, Xu Y, Sadaf Farooqi I. Human loss-of-function variants in the serotonin 2C receptor associated with obesity and maladaptive behavior. *Nat Med*.2022;28(12):2537-2546.

69. Liu H, He Y, Liu H, Brouwers B, Yin N, Lawler K, Keogh JM, Henning E, Lee DK, Yu M, Tu L, Zhang N, Conde KM, Han J, Yan Z, Scarcelli NA, Liao L, Xu J, Tong Q, Zheng H, Sun Z, Yang Y, Wang C, He Y, Farooqi IS, Xu Y. Neural circuits expressing the serotonin 2C receptor regulate memory in mice and humans. *Sci Adv*.2024;10(26):eadl2675.

70. Li Y, Cacciottolo TM, Yin N, He Y, Liu H, Liu H, Yang Y, Henning E, Keogh JM, Lawler K, Mendes de Oliveira E, Gardner EJ, Kentistou KA, Laouris P, Bounds R, Ong KK, Perry JRB, Barroso I, Tu L, Bean JC, Yu M, Conde KM, Wang M, Ginnard O, Fang X, Tong L, Han J, Darwich T, Williams KW, Yang Y, Wang C, Joss S, Firth HV, Xu Y, Farooqi IS. Loss of transient receptor potential channel 5 causes obesity and postpartum depression. *Cell*.2024;187(16):4176-4192 e4117.

71. Asai M, Ramachandrappa S, Joachim M, Shen Y, Zhang R, Nuthalapati N, Ramanathan V, Strochlic DE, Ferket P, Linhart K, Ho C, Novoselova TV, Garg S, Ridderstrale M, Marcus C, Hirschhorn JN, Keogh JM, O'Rahilly S, Chan LF, Clark AJ, Farooqi IS, Majzoub JA. Loss of function of the melanocortin 2 receptor accessory protein 2 is associated with mammalian obesity. *Science*.2013;341(6143):275-278.

72. Pearce LR, Atanassova N, Banton MC, Bottomley B, van der Klaauw AA, Revelli JP, Hendricks A, Keogh JM, Henning E, Doree D, Jeter-Jones S, Garg S, Bochukova EG, Bounds R, Ashford S, Gayton E, Hindmarsh PC, Shield JP, Crowne E, Barford D, Wareham NJ, consortium UK, O'Rahilly S, Murphy MP, Powell DR, Barroso I, Farooqi IS. KSR2 mutations are associated with obesity, insulin resistance, and impaired cellular fuel oxidation. *Cell*.2013;155(4):765-777.